Teuza - A Fairchild Technology Venture Ltd.
TEUZF
Other OTC0.20
USD
- -
- -
Teuza - A Fairchild Technology Venture Ltd.
TEUZF
(Other OTC)
Recent
price
0.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Teuza - A Fairchild Technology Venture Ltd. (TUZA:TLV; TEUZF) is an Israel-based venture capital firm specializing in early-stage equity investments across technology sectors including software, semiconductors, communications, electronics, information technology, biotechnology, healthcare, medical devices, and telecommunications. The firm provides seed, pre-seed, startup, expansion capital, and mezzanine financing, typically investing $1 million to $2 million per deal for 25% to 49% equity stakes while securing board representation to support portfolio companies in strategy, market entry, capital raising, and international expansion into regions such as the United States, Europe, China, Japan, Canada, and Israel. Its historical portfolio has featured companies like Nova Measuring Instruments Ltd., Bioness Inc., Sagantec, Qualion, ADT, ANTT, Monitel, Digiflex, Media Boost, TytoCare, and Kidas, delivering hands-on operational assistance and exits via IPOs or M&A transactions. Founded in 1992 and one of Israel's pioneering venture capital funds, Teuza is headquartered at 49 Hahistadrut Street, Haifa, Israel, and is publicly traded on the Tel Aviv Stock Exchange; the fund is managed by Teuza Management and Development Ltd. under CEO and founder Avi Kerbs. In recent years, Teuza has navigated portfolio developments including the 2021 sale of Bioness Inc. to Bioventus for $110 million, amid disputes over the transaction process resolved in Delaware Chancery Court, alongside continued focus on medtech and biotech through events like BIZHEALTH sessions on FDA strategy and reimbursement in 2024-2025. The firm maintains active deal flow in innovative ventures without disclosed new funding rounds, major acquisitions, or strategic alliances in the past 1-2 years, emphasizing sustained support for high-potential Israeli and international startups.